Table 1. Characteristics of patients with body mass index (BMI)≥25 or <25 kg/m2.
| Overweight or obese: BMI≥25 kg/m2 (n = 129) | Normal weight: BMI<25 kg/m2 (n = 110) | P value | |
| BMI(kg/m2) | 26.9±1.9 | 22.0±1.6 | <0.05 |
| Age (yrs) | 55±12 | 58±9 | <0.05 |
| Men (%) | 94/129(72.9%) | 85/110(77.3%) | NS |
| AF duration (yrs) | 6.4±7.1 | 6.7±5.6 | NS |
| Nonparoxysmal AF | 50/129(38.8%) | 29/110(26.4%) | <0.05 |
| Smoking | 50/129(38.8%) | 41/110(37.2%) | NS |
| Diabetes mellitus(%) | 20/129(15.5%) | 7/110(6.4%) | <0.05 |
| Hypertension(%) | 76/129(58.9%) | 45/110(40.9%) | <0.05 |
| CHD(%) | 6/129(4.7%) | 5/110(4.5%) | NS |
| Serum creatinine (umol/L) | 81±15 | 81±13 | NS |
| Systolic blood pressure (mmHg) | 130±16 | 126±15 | NS |
| Diastolic blood pressure (mmHg) | 79±13 | 77±11 | NS |
| Heart rate (bpm) | 79±18 | 76±15 | NS |
| LAD (mm) | 43±7 | 41±8 | <0.05 |
| LVEDD (mm) | 50±4 | 49±5 | <0.05 |
| LVEF (%) | 62±7 | 62±7 | NS |
| Medications | |||
| Warfarin(%) | 6/129(4.7%) | 4/110(3.6%) | NS |
| Aspirin(%) | 24/129(18.6%) | 21/110(19.1%) | NS |
| ACEI/ARB(%) | 47/129(36.4%) | 24/110(21.8%) | <0.05 |
| Statin(%) | 9/129(7.0%) | 6/110(5.5%) | NS |
| CCB(%) | 16/129(12.4%) | 5/110(4.5%) | <0.05 |
| βblocker(%) | 42/129(32.6%) | 33/110(30%) | NS |
| Profenanone(%) | 19/129(14.7%) | 17/110(15.5%) | NS |
| Amiodarone(%) | 23/129(17.8%) | 18/110(16.4%) | NS |
| NT-proBNP(fmol/ml) | 437(324–550) | 501(447–638) | <0.05 |
| Log NT-proBNP | 2.62±0.18 | 2.75±0.15 | <0.001 |
CHD = Coronary heart disease; LAD = Left atrial diameter; LVEDD = Left ventricular end diastolic diameter; LVEF = Left ventricular ejection fraction; ACEI = Angiotensin-converting enzyme inhibitor; ARB = Angiotensin receptor blocker; CCB = Calcium channel blocker; NT-proBNP = N-terminal proB-type natriuretic peptide; NS = No significant.